 Home > Active Ingredient News > Study of Nervous System > Courier's potential "first-in-class" DMD new drug Phase 2b clinical trial results published!

Courier's potential "first-in-class" DMD new drug Phase 2b clinical trial results published!

 Last Update: 2022-09-06
 Source: Internet
 Author: User

▎Edited by WuXi AppTec Content Team

Today, Santhera Pharmaceuticals and ReveraGen BioPharma jointly announced the positive results of the VISION-DMD clinical 2b trial of Duchenne muscular dystrophy (DMD) investigational drug vamorolone, published in the leading journal JAMA Neurology

DMD is a rare X-chromosome-linked genetic disorder caused by mutations in the gene encoding dystrophin on the X chromosome, and therefore affects almost exclusively male patients and is one of the most common childhood neuromuscular diseases one

▲Molecular formula of Vamorolone (Image source: Fvasconcellos (talk · contribs), Public domain, via Wikimedia Commons)

The data published this time showed that vamorolone met the primary endpoint of the trial at 24 weeks

▲If you have any business needs, please long press to scan the QR code above, or

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Top Product

$10-13/UNIT FOB

Pregabalin

CAS No.: 148553-50-8

Pharmaceutical

$165/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.